Beilei Liu

1.8k total citations · 2 hit papers
20 papers, 883 citations indexed

About

Beilei Liu is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Beilei Liu has authored 20 papers receiving a total of 883 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 6 papers in Oncology and 6 papers in Immunology. Recurrent topics in Beilei Liu's work include RNA modifications and cancer (4 papers), HIV Research and Treatment (3 papers) and Epigenetics and DNA Methylation (3 papers). Beilei Liu is often cited by papers focused on RNA modifications and cancer (4 papers), HIV Research and Treatment (3 papers) and Epigenetics and DNA Methylation (3 papers). Beilei Liu collaborates with scholars based in China, Hong Kong and United States. Beilei Liu's co-authors include Xin‐Yuan Guan, Licheng Tan, Hongyu Zhou, Xiaona Fang, Lanqi Gong, Yu Zhang, Qian Yan, Li Fu, Tuxiong Huang and Kaisheng Liu and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Communications and Cancer Research.

In The Last Decade

Beilei Liu

18 papers receiving 872 citations

Hit Papers

Exploring treatment options in cancer: tumor treatment st... 2024 2026 2025 2024 2024 100 200 300 400

Peers

Beilei Liu
Yawen Guo China
Xu He China
Zheng Han China
Beilei Liu
Citations per year, relative to Beilei Liu Beilei Liu (= 1×) peers Alakesh Das

Countries citing papers authored by Beilei Liu

Since Specialization
Citations

This map shows the geographic impact of Beilei Liu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Beilei Liu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Beilei Liu more than expected).

Fields of papers citing papers by Beilei Liu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Beilei Liu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Beilei Liu. The network helps show where Beilei Liu may publish in the future.

Co-authorship network of co-authors of Beilei Liu

This figure shows the co-authorship network connecting the top 25 collaborators of Beilei Liu. A scholar is included among the top collaborators of Beilei Liu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Beilei Liu. Beilei Liu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zheng, Yide, Rui Mao, Beilei Liu, et al.. (2025). Thermally stabilized polyacrylonitrile for flexible triboelectric devices operating from −29 °C to 400 °C. Chemical Engineering Journal. 518. 164573–164573. 3 indexed citations
2.
Liu, Qin, Jie Luo, Shanshan Li, et al.. (2025). SOX4-ZIP14-zinc metabolism mediates oncogenesis and suppresses T cell immunity in nasopharyngeal carcinoma. Cell Reports Medicine. 6(9). 102300–102300.
3.
Liu, Beilei, Jiayu Sun, Wenxiu Li, et al.. (2025). 3D Nanofibrillar Matrix Stiffness Modulates Extracellular Vesicle Cargo and Pro‐Tumour Functions. Journal of Extracellular Vesicles. 14(10). e70165–e70165.
4.
Zhou, Hong-Yu, Licheng Tan, Baifeng Zhang, et al.. (2024). GPRC5A promotes lung colonization of esophageal squamous cell carcinoma. Nature Communications. 15(1). 9950–9950. 2 indexed citations
5.
Huang, Jiao, Xiaona Fang, Yu Zhang, et al.. (2024). FASN Inhibition Decreases MHC-I Degradation and Synergizes with PD-L1 Checkpoint Blockade in Hepatocellular Carcinoma. Cancer Research. 84(6). 855–871. 54 indexed citations breakdown →
6.
Liu, Beilei, et al.. (2024). Exploring treatment options in cancer: tumor treatment strategies. Signal Transduction and Targeted Therapy. 9(1). 175–175. 412 indexed citations breakdown →
7.
Zhou, Hongyu, Licheng Tan, Beilei Liu, & Xin‐Yuan Guan. (2023). Cancer stem cells: Recent insights and therapies. Biochemical Pharmacology. 209. 115441–115441. 33 indexed citations
8.
Liu, Xiaoping, Zhanbin Li, Shengdong Cheng, et al.. (2023). The change of ecosystem resilience and its response to economic factors in Yulin, China. Environmental Research Communications. 5(4). 45006–45006. 8 indexed citations
9.
Liu, Beilei, Baifeng Zhang, Hongyu Zhou, et al.. (2023). Targeting MFGE8 secreted by cancer-associated fibroblasts blocks angiogenesis and metastasis in esophageal squamous cell carcinoma. Proceedings of the National Academy of Sciences. 120(42). e2307914120–e2307914120. 24 indexed citations
10.
Liu, Beilei, et al.. (2022). The Role of Tumor Microenvironment in Invasion and Metastasis of Esophageal Squamous Cell Carcinoma. Frontiers in Oncology. 12. 911285–911285. 20 indexed citations
11.
Liu, Beilei, Xiaona Fang, Dora Lai‐Wan Kwong, et al.. (2022). Targeting TROY-mediated P85a/AKT/TBX3 signaling attenuates tumor stemness and elevates treatment response in hepatocellular carcinoma. Journal of Experimental & Clinical Cancer Research. 41(1). 182–182. 27 indexed citations
12.
Gong, Lanqi, Yu Zhang, Qian Yan, et al.. (2022). Inhibition of lysyl oxidase‐like 2 overcomes adhesion‐dependent drug resistance in the collagen‐enriched liver cancer microenvironment. Hepatology Communications. 6(11). 3194–3211. 15 indexed citations
13.
Huang, Tuxiong, Xiangyu Tan, Yuting Li, et al.. (2021). Targeting cancer-associated fibroblast-secreted WNT2 restores dendritic cell-mediated antitumour immunity. Gut. 71(2). 333–344. 142 indexed citations
14.
Yu, Liang, Qian Yan, Lanqi Gong, et al.. (2021). Correction: C-terminal truncated HBx initiates hepatocarcinogenesis by downregulating TXNIP and reprogramming glucose metabolism. Oncogene. 40(35). 5451–5453. 6 indexed citations
15.
Zhang, Yu, Qian Yan, Lanqi Gong, et al.. (2020). C-terminal truncated HBx initiates hepatocarcinogenesis by downregulating TXNIP and reprogramming glucose metabolism. Oncogene. 40(6). 1147–1161. 72 indexed citations
16.
Jiang, Zhiqiang, Hang Yu, Beilei Liu, et al.. (2019). Polymorphisms in the APOBEC3G gene of Chinese rhesus macaques affect resistance to ubiquitination and degradation mediated by HIV-2 Vif. Archives of Virology. 164(5). 1353–1360. 1 indexed citations
17.
Gong, Lanqi, Qian Yan, Yu Zhang, et al.. (2019). Cancer cell reprogramming: a promising therapy converting malignancy to benignity. Cancer Communications. 39(1). 48–48. 55 indexed citations
18.
Liu, Beilei, Yabin Jin, Yonghui Zhang, et al.. (2015). Comprehensive identification of high-frequency and combination MHC-DMA and -DMB alleles in a cohort of Chinese rhesus macaques and cynomolgus macaques of Vietnamese origin. Human Immunology. 76(2-3). 109–112. 2 indexed citations
19.
Zhang, Huiling, Feng‐Liang Liu, Yabin Jin, et al.. (2015). The effects of TRIM5α polymorphism on HIV-2ROD and SIVmac239 replication in PBMCs from Chinese rhesus macaques and Vietnamese-origin cynomolgus macaques. Virology. 487. 222–229. 4 indexed citations
20.
Zhang, Huiling, et al.. (2014). Comprehensive identification of MHC class II alleles in a cohort of Chinese rhesus macaques. Immunogenetics. 66(9-10). 575–580. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026